Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2026 Earnings Call Transcript February 12, 2026 Aethlon Medical, Inc. misses on ...
An fresh look at trial results that propelled the only FDA approval of a chimeric antigen receptor (CAR) T-cell therapy for mantle cell lymphoma (MCL) shows prior treatment with ibrutinib, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results